Case Study: The Patent That Was Rejected — And How the Inventor Saved It

This case study is a realistic composite illustrating how experienced patent prosecution turns an initial rejection into a granted patent. The technical details and prosecution strategy reflect common patterns in USPTO examination.

The Invention

David, a materials scientist in Texas, developed a self-healing concrete additive — microcapsules containing a sodium silicate healing agent embedded in a polymer shell. When a crack propagated through the concrete and ruptured a capsule, the sodium silicate reacted with calcium hydroxide in the concrete matrix to form a calcium-silicate-hydrate seal, closing the crack without human intervention.

David's patent attorney filed a US non-provisional application with claims covering the microcapsule composition, the method of incorporating capsules into concrete, and the self-healing mechanism.

The First Office Action: Rejection

Nine months after filing, the examiner issued a non-final Office Action rejecting all claims on two grounds:

Rejection 1 — Obviousness (§ 103): The examiner combined two prior art references. Reference A was a 2015 Japanese patent describing sodium silicate microcapsules for coating applications (not concrete). Reference B was a 2018 US publication describing self-healing concrete using bacterial agents (not sodium silicate). The examiner argued that a skilled person, knowing that sodium silicate could be encapsulated (Reference A) and that self-healing concrete was a known concept (Reference B), would have found it obvious to combine them.

Rejection 2 — Enablement (§ 112): The examiner argued that the specification did not adequately teach how to produce microcapsules with the claimed shell thickness range (5–50 microns) — noting that the specification described only one specific shell thickness (20 microns) in the working example, and that a skilled person would need undue experimentation to achieve the full range.

David's first instinct was to narrow the claims — reduce the shell thickness range, add limitations from the dependent claims, and accept whatever survived. His attorney recommended a different approach.

The Response Strategy

Step 1: Request an Examiner Interview

Before drafting the written response, David's attorney called the examiner and scheduled a 20-minute telephone interview. During the interview, the attorney learned two critical things:

The examiner acknowledged that the combination of References A and B was "not the strongest rejection" but felt that the general concept of encapsulation + self-healing was obvious. The examiner was open to arguments showing that the specific combination produced unexpected results.

The examiner's real concern on enablement was narrow: the specification needed to explain how shell thickness was controlled during encapsulation — not just state the range.

This information shaped the entire response strategy. Without the interview, the attorney would have guessed at the examiner's reasoning; with the interview, the response addressed the examiner's actual concerns.

Step 2: Argue Obviousness — Don't Amend

The attorney's response argued — without amending the claims:

The combination was not obvious. Reference A described sodium silicate capsules for coating applications, where the capsules were designed to rupture under UV exposure. Reference B described bacterial self-healing, where living organisms sealed cracks through biological mineralisation. Neither reference suggested using encapsulated sodium silicate in a concrete matrix — and the mechanisms were fundamentally different. A skilled person reading Reference A would not have been motivated to move the technology from coatings to concrete, because the rupture trigger (UV exposure vs mechanical crack propagation) was entirely different.

Unexpected results. David's specification included test data showing that the calcium-silicate-hydrate seal formed by his capsules restored 95% of the original concrete's compressive strength — far exceeding the 40–60% strength recovery reported in bacterial self-healing systems (Reference B). This was not a predictable outcome from the combination of the references. The attorney submitted a declaration from David with comparative data.

Teaching away. Reference A explicitly stated that the polymer shell was designed to degrade under UV irradiation — a property that would be detrimental in concrete (which is not exposed to UV after curing). A skilled person following Reference A's teaching would have been led away from using those capsules in concrete, not toward it.

Step 3: Address Enablement With Additional Disclosure

For the enablement rejection, the attorney did not amend the claims. Instead, the response included:

A declaration from David explaining that shell thickness in interfacial polymerisation (the encapsulation method described in the specification) is controlled by three well-known parameters: reaction time, monomer concentration, and agitation speed. The declaration provided the specific parameter ranges for achieving 5-micron, 20-micron, and 50-micron shells — information that was within the knowledge of a skilled encapsulation chemist but had not been explicitly stated in the specification.

The attorney argued that a person skilled in interfacial polymerisation would not require undue experimentation to achieve the claimed range — the three control parameters were well-understood in the field, and the specification provided a working example at the midpoint of the range.

The Outcome

The examiner issued a Notice of Allowance four months after the response — allowing all claims without amendment. The patent was granted with the original broad claim scope intact.

What made the difference:

The examiner interview saved months. Understanding the examiner's actual concerns — rather than guessing — allowed a targeted response that addressed the right issues.

Arguing rather than amending preserved claim scope. If David had amended the claims to specify only 20-micron shells (the worked example), competitors could have used 15-micron or 30-micron shells without infringing. By keeping the 5–50 micron range, the patent covered the entire useful range.

Unexpected results defeated obviousness. The 95% strength recovery — documented with comparative data — was the key evidence. Without it, the examiner might have maintained the obviousness rejection.

The Lessons

Do not panic at a first Office Action. The vast majority of US patent applications receive at least one rejection. A first Office Action is the beginning of a conversation, not the end of the road. The examiner is testing the boundaries of your claims — not delivering a final verdict.

Request an examiner interview before responding in writing. A 20-minute call costs $0 in government fees and typically $500–$1,000 in attorney time. It is the highest-ROI action available during prosecution.

Argue before you amend. Every amendment narrows your claims permanently through prosecution history estoppel. Arguments — if successful — preserve the original scope. Amend only when argument has been exhausted or when the amendment is minimal and strategically advantageous.

Unexpected results are your strongest obviousness defence. If your invention produces results that a skilled person would not have predicted from the prior art, document those results in the specification and be prepared to submit declarations with comparative data during prosecution.

The specification is your insurance policy. David's enablement rejection was overcome with a declaration explaining what the specification already implied. But if the specification had been thinner — without the working example, without the description of interfacial polymerisation — the enablement rejection might have been fatal. Invest in a thorough specification at the time of filing.

Sources

1. 35 U.S.C. § 103 — Obviousness — Statutory basis for the obviousness rejection and the unexpected results defence
2. 35 U.S.C. § 112 — Enablement — Statutory basis for the enablement rejection regarding specification adequacy
3. MPEP § 713 — Examiner Interviews — USPTO guidance on requesting and conducting examiner interviews
4. MPEP § 2145 — Rebuttal Arguments — Guidelines for responding to obviousness rejections with unexpected results evidence